regeneron news - Search News

Dupixent, Regeneron

Benzinga.com · 2d

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025.

GlobalData on MSN · 2d

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Business Insider · 2d

Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License

MarketWatch · 2d

Regeneron, Sanofi Get New FDA Review of Dupixent for CSU

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in CSU, which causes sudden and debilitating hives and recurring itch.

3d

Unlocking future medicines: The crucial role of clinical trials

Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

1d

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup

Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a hold rating in a research note ...

Fintel on MSN1d

Wolfe Research Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Outperform Recommendation

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with ...

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...

2don MSN

Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings

Dallas salon owner Shelley Luther discusses her comeback after being jailed for keeping her small business open during COVID ...

2d

Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...

13d

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

3d

2 Top Growth Stocks to Buy on the Dip

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

2d

Check Out What Whales Are Doing With REGN

Looking at options history for Regeneron Pharmaceuticals REGN we detected 8 trades. If we consider the specifics of each ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results